source
- EyePoint's Phase 3 trial fails, prompting 53% staff cuts; Lilly signs China drug delivery partnershipEyePoint, a Watertown, Massachusetts biotech, reported that its experimental therapy did not meet primary endpoints in a Phase 3 study, marking a setback for the company. Following the trial failu…
- China proposes new limits on foreign biotech acquisitions to protect domestic drug developmentChina is drafting new rules that would restrict foreign companies from acquiring Chinese biotech assets deemed critical to the nation's drug development sector. The proposal aims to keep control o…